Latest research on Herceptin

A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*

Herceptin side effects

As shown in Fig. S8†, SKBR-3 tumor cells pretreated with Herceptin decrease 40.9% fluorescence intensity in comparison of non-pretreated group. [source, 2016]
The contribution by trileucine seems to be marginal, whereas selection of BSA as standard significantly increased the estimated value of the protein that would have been correctly obtained with Herceptin as standard. [source, 2015]
The nanoconjugate contains five key components (Figure 1B): PMLA as the backbone; 2% Morpholino antisense oligonucleotide (AONHER2) to inhibit HER2/neu protein synthesis; 0.2% Herceptin, 40% tri(L-Leucine) (LLL) for cytoplasmic delivery of AONHER2, and 5% mPEG5000 to increase serum stability. [source, 2015]
Because of this, Herceptin is usually administered in combination with chemotherapies, such as Paclitaxel or Docetaxel, which increase response rates, time to disease progression and overall survival [50]. [source, 2015]
Therefore, the GNP conjugated with Herceptin could increase the death of SK-BR3 cells considerably compared to the GNP without Herceptin. [source, 2015]
A probable explanation of this large decrease in cell viability in the case of GNP–Her is that intracellularly distributed Herceptin shows significant apoptotic activity by networking with several transcription factors related to cell propagation. [source, 2015]
After Herceptin conjugation, the NPs’ interaction with SK-BR cells was amplified significantly, in contrast to that of the original NPs, and increased to 1.4 pg per cell within the first day of culture, much higher than that of the original NPs. [source, 2015]
Ithimakin et al39 note an interesting implication for the efficacy of the adjuvant trastuzumab: Herceptin and other antagonists of HER2 could have positive therapeutic benefits outside of its traditional realm of HER2 amplification, simply because of effects on CSCs. [source, 2015]
During the treatment with Herceptin, she required stopping it few times and manage her cardiac ejection fraction EF decreased. [source, 2015]
Immunohistochemical staining performed 6 h after radiation also showed that rhNRG-1β pretreatment ameliorated the myocardial injury caused by irradiation, but ErbB2 blockage by Herceptin nearly eliminated the protective effects of rhNRG-1β on the myocardium (Vehicle, P<0.001 versus Control; NRG, P<0.001 versus Vehicle; H+NRG, P<0.001 versus NRG, P>0.05 versus Vehicle; n = 5 per group). [source, 2015]